Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma

The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CAP) or cyclophosphamide, doxor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta obstetricia et gynecologica Scandinavica 1994-09, Vol.73 (8), p.658-662
Hauptverfasser:	Ron, Ilan-Gil, Inbar, Moshe, Gelernter, Ilana, Lewysohn, Orly, Ayalon, Daniel, Dale, Janet, Chaitchik, Samario
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - immunology Adenocarcinoma - pathology Adult advanced ovarian carcinoma Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences CA-125 Antigen - immunology CA-125 serum level chemotherapy Cisplatin - therapeutic use Cyclophosphamide - therapeutic use Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Ovarian Neoplasms - drug therapy Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Prognosis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CAP) or cyclophosphamide, doxorubicin and cisplatinum (CAP). Patients with serum CA-125 values below the normal value of 35 U/ml after two courses had a significantly longer median survival (p
ISSN:	0001-6349 1600-0412
DOI:	10.3109/00016349409013462